An Open-Label Study Investigating Differences Between Women and Men
The first national study to determine HIV drug dosing differences between men and women.
There are 15 sites throughout the country. For enrollment information please call: 1.800.554.4876.
UCLA -- 310.206.6414
Offers a wide variety of clinical studies for women, by a team of women researchers.
OI Therapies (UCLA)
For people at risk for CMV: To evaluate the effectiveness and safety of oral valganciclovir (a new compound) for the prevention of CMV.
Fluconazole for oral candida; chronic vs. episodic treatment.
Antiviral Therapy and Lipids
The study is to research the relationship between antiviral therapy and lipodystrophy (fat distribution). All meds, study visits and lab tests are free. Participants will receive $25 per visit after the 1st two visits (up to $300). Enrolling men and women with greater than 50 T-cells, a viral load between 1,000 and 200,000. Participants will receive triple-drug therapy for 2 years.
Pravachol and Tricor will be tested for their effectiveness against lipodystrophy. The trial lasts for 48 weeks. Eligible participants must be on a lipid-lowering diet and have been exercising for 30 days prior to being screened for the study. Must have been treated with anti-HIV drugs for more than 6 months and have been taking them regularly for 4 weeks or 8 weeks if you've changed from a PI to a non-PI. Women participants must be willing to take 2 reliable types of birth control. There is no T-cell or Viral Load requirement, however, triglyceride levels must be at least 200mg/d1 and a low-density lipoprotein (LDL) level of at least 130 mg/dl, 3 after fasting for 8 to 12 hours.
What Causes Lipids?
ACTG #5078 will try to find out. Three groups of people will be studied. Group #1: HIV-positive individuals with a viral load less than 10,000 and currently taking a PI. Group #2: HIV-positive individuals with a viral load less than 10,000 and not taking a PI with their current regimen. Group #3: HIV-negative individuals. This is a 2-year trial. Blood tests and ultrasound measurements of the carotid artery will be performed every 6 months. Exclusions are a viral load over 10,000 or a history of cardiovascular disease and/or pregnancy.
HAART and IL-2
Men and women who are already on a stable HAART regimen are needed. Participants will be monitored every 8 weeks for one year and every 4 months thereafter. Viral load must be less than 10,000 with T-cells between 50 and 299. Certain AIDS defining OIs, and having participated in an IL-2 trial will exclude participants. Contact the study nurse for specifics. The objection of this study is to determine the clinical effectiveness of recombinant, human interleukin-2 on delaying the onset of AIDS-defining illness.
For Pregnant Women (UCLA)
Study 321: Phase I, Safety, Tolerance and Pharmacokinetics of Abacavir (Ziagen) with standard AZT Therapy in newborns of HIV infected women.
Study 326: Phase I & II -- all babies will get AZT. Most will get a vaccine that might help them fight off HIV.
Study 331: to decide the dose of AZT for HIV exposed premature infants.
USC -- 213.343.8324
Llame al 213.740.0299
A wide variety of clinical studies are open to women, including trials with antivirals and protease inhibitors. Also those looking to prevent and treat opportunistic infections.
For Pregnant Women (USC)
This is a Phase I study of Viracept and Combivir in HIV infected pregnant women and their infants. Participants will receive Viracept and Combivir through the study and 12 weeks after delivery. Newborns will begin taking Viracept, Combivir when they can take liquids and continue for six weeks. Women will have study visits every two weeks until week 36 of their pregnancy, then every 6 weeks until the start of labor. Infants will have study visits at eight days, three weeks, six weeks, three months and six months of age. Call Eve Openskolski at 323.226.2342.
La Escuela de asistencia social en la U.S.C. está llevando a cabo una encuesta de encuesta es completamente confidencial, y se paga $20.
Other Research Efforts
If you think you might have a recent exposure to HIV, give us a call -- 213.351.8195 ext.8175.
HIV+ Women Needed
Women ages 18-50 are needed for a study to measure the effects of testosterone replacement on body weight, and muscle mass. Incentive payments provided. Call 310.222.8152.
HAART and Remune
Phase III study, placebo controlled. Must have never taken antivirals. For more information please call 310.358.2429.
World Wide Trial
Evaluation of ABT-378/ritonavir, a new protease inhibitor. This study is in the early phases. 1.800.313.2130.
Donate Your Brain
A project to study the effects of HIV on the brain. You must donate your brain after your death. 800.791.4966.